Literature DB >> 4007040

Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension.

V D'Arcy, M Laher, D McCoy, P Sullivan, C H Walsh, M P Hickey.   

Abstract

Twenty three patients with essential hypertension who were uncontrolled on diuretic and/or beta-receptor antagonist therapy were treated additionally with the vasodilator, pinacidil, in an open study. Significant reduction in mean blood pressure was achieved. Supine and erect systolic and diastolic blood pressure fell by 44/25 mmHg and 37/24 mmHg respectively over the study period of 12 weeks. Side-effects such as dizziness, headache, facial flushing and mild oedema were experienced by 10 patients during the study, all of which were mild and transient and did not require withdrawal from pinacidil therapy. Pinacidil is an effective and well tolerated agent in the treatment of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4007040     DOI: 10.1007/bf00543335

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

Review 1.  Medical intelligence drug therapy.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1976-08-05       Impact factor: 91.245

2.  Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension.

Authors:  A C Guyton; T G Coleman; A V Cowley; K W Scheel; R D Manning; R A Norman
Journal:  Am J Med       Date:  1972-05       Impact factor: 4.965

3.  N"-Cyano-N-4-pyridyl-N'-1,2,2-trimethyl-propylguanidine, a new vasodilating agent: acute effect of blood pressure and pharmacokinetics in hypertensive patients.

Authors:  T Kardel; T Hilden; J Carlsen; J Trap-Jensen
Journal:  J Cardiovasc Pharmacol       Date:  1981 Sep-Oct       Impact factor: 3.105

4.  Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.

Authors:  H J Petersen; C K Nielsen; E Arrigoni-Martelli
Journal:  J Med Chem       Date:  1978-08       Impact factor: 7.446

5.  N''-cyano-N-4-pyridyl-N'-1,2,2-trimethylpropylguanidine, monohydrate (P 1134): a new, potent vasodilator.

Authors:  E Arrigoni-Martelli; C K Nielsen; U B Olsen; H J Petersen
Journal:  Experientia       Date:  1980-04-15

6.  Immediate central and peripheral haemodynamic effects of a new vasodilating agent Pinacidil (P1134) in hypertensive man.

Authors:  J E Carlsen; T Kardel; T Hilden; M Tangø; J Trap-Jensen
Journal:  Clin Physiol       Date:  1981-08

7.  Diuretic and beta-blocker in hypertension--then what?

Authors:  L E Ramsay
Journal:  J R Coll Physicians Lond       Date:  1980-10
  7 in total
  4 in total

Review 1.  Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H A Friedel; R N Brogden
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

2.  K(ATP) channel expression and pharmacological in vivo and in vitro studies of the K(ATP) channel blocker PNU-37883A in rat middle meningeal arteries.

Authors:  K B Ploug; L J Boni; M Baun; A Hay-Schmidt; J Olesen; I Jansen-Olesen
Journal:  Br J Pharmacol       Date:  2008-03-10       Impact factor: 8.739

3.  The KATP channel in migraine pathophysiology: a novel therapeutic target for migraine.

Authors:  Mohammad Al-Mahdi Al-Karagholi; Jakob Møller Hansen; Johanne Severinsen; Inger Jansen-Olesen; Messoud Ashina
Journal:  J Headache Pain       Date:  2017-08-23       Impact factor: 7.277

Review 4.  ATP-Sensitive Potassium Channels in Migraine: Translational Findings and Therapeutic Potential.

Authors:  Amalie Clement; Song Guo; Inger Jansen-Olesen; Sarah Louise Christensen
Journal:  Cells       Date:  2022-08-04       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.